EUVIMEDEUVIMED entdecken
Crossref

lnc-MTRNR2L12-3 derived from hypoxic breast cancer cell exosomes facilitates angiogenesis via the Src/FAK signaling pathway

Li Zheng, Juanfen Mo, Xuesong He, Qi Xu, Yi Bao, Jiayuan Wu

Medical Oncology · 2025

DOI: 10.1007/s12032-025-02836-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, 2025. Verfasst von Li Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Exosomes, Breast Neoplasms, Neovascularization, Pathologic, RNA, Long Noncoding. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Science and Technology Bureau of Jiaxing City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exosomal long non-coding RNAs (lncRNAs) play crucial roles in breast cancer progression. However, the mechanisms by which hypoxia-induced exosomes mediate angiogenesis through lncRNAs in the tumor microenvironment remain largely unexplored. In this study, exosomes were isolated and characterized from MDA-MB-231 breast cancer cells under normoxic and hypoxic conditions. Hypoxia-induced exosomes (Hyp-exo) were shown to significantly promote angiogenesis. Microarray analysis revealed that lnc-MTRNR2L12-3 was highly enriched in Hyp-exo compared to normoxic exosomes (NC-exo). Functional studies, both in vitro and in vivo, demonstrated that exosomal lnc-MTRNR2L12-3 derived from hypoxic breast cancer cells substantially enhanced angiogenesis. Mechanistically, PCR array and western blot analysis confirmed that silencing lnc-MTRNR2L12-3 inhibited Src/FAK signaling pathway activation in HUVECs, while hypoxia-induced exosomes effectively rescued this suppression. Overall, hypoxia-induced breast cancer exosomes deliver lnc-MTRNR2L12-3 to endothelial cells, promoting angiogenesis through the Src/FAK signaling pathway. These findings provide new insights into targeting angiogenesis in the tumor microenvironment for breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesBreast NeoplasmsNeovascularization, PathologicRNA, Long Noncodingsrc-Family KinasesFocal Adhesion Kinase 1HumansFemaleSignal TransductionAnimalsCell Line, TumorMiceHuman Umbilical Vein Endothelial CellsTumor MicroenvironmentMice, NudeCell HypoxiaMice, Inbred BALB CAngiogenesis

Stichwörter der Autor:innen

AngiogenesisBreast cancerExosomeHypoxiaLnc-MTRNR2L12-3Src/FAK signaling pathway

Substanzen

RNA, Long Noncodingsrc-Family KinasesFocal Adhesion Kinase 1PTK2 protein, human

Autor:innen und Institutionen

  • The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, Zhejiang, People's Republic of China.
  • Department of Breast Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, Zhejiang, People's Republic of China.
  • The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, Zhejiang, People's Republic of China. wujiayuan@zjxu.edu.cn.

Förderung

  • Natural Science Foundation of Zhejiang Province
  • Science and Technology Bureau of Jiaxing City

Zitieren

APA

Zheng, L., Mo, J., He, X., Xu, Q., Bao, Y., & Wu, J. (2025). lnc-MTRNR2L12-3 derived from hypoxic breast cancer cell exosomes facilitates angiogenesis via the Src/FAK signaling pathway. Medical Oncology. https://doi.org/10.1007/s12032-025-02836-9

Vancouver

Zheng L, Mo J, He X, Xu Q, Bao Y, Wu J. lnc-MTRNR2L12-3 derived from hypoxic breast cancer cell exosomes facilitates angiogenesis via the Src/FAK signaling pathway. Medical Oncology. 2025. doi:10.1007/s12032-025-02836-9

BibTeX
@article{Zheng2025,
  author = {Zheng, Li and Mo, Juanfen and He, Xuesong and Xu, Qi and Bao, Yi and Wu, Jiayuan},
  title = {lnc-MTRNR2L12-3 derived from hypoxic breast cancer cell exosomes facilitates angiogenesis via the Src/FAK signaling pathway},
  journal = {Medical Oncology},
  year = {2025},
  doi = {10.1007/s12032-025-02836-9}
}
Kostenlos starten →